Compare RYAAY & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYAAY | WAT |
|---|---|---|
| Founded | 1985 | 1958 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.8B | 33.5B |
| IPO Year | 2003 | 1996 |
| Metric | RYAAY | WAT |
|---|---|---|
| Price | $56.59 | $410.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 17 |
| Target Price | $78.00 | ★ $379.19 |
| AVG Volume (30 Days) | ★ 1.1M | 859.1K |
| Earning Date | 05-18-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | N/A | ★ 0.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.99 | $104.66 |
| Revenue Next Year | $6.32 | $10.40 |
| P/E Ratio | $12.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $53.14 | $282.77 |
| 52 Week High | $74.24 | $421.74 |
| Indicator | RYAAY | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 41.94 | 58.46 |
| Support Level | $55.78 | $372.18 |
| Resistance Level | $61.54 | N/A |
| Average True Range (ATR) | 1.07 | 11.45 |
| MACD | -0.29 | -0.60 |
| Stochastic Oscillator | 33.18 | 62.64 |
Ryanair is Europe's largest low-cost airline, known for its extensive network and highly efficient business model. Operating over 3,600 flights daily across 240-plus destinations in 40 countries, Ryanair has built its success on offering affordable air travel while maintaining tight control over costs. The airline primarily uses Boeing 737 aircraft, including the newer 737 8-200 "Gamechanger" variant, which simplifies operations and reduces expenses. Ryanair focuses on high passenger volume, ancillary revenue, and operational efficiency, ensuring its position as a leading airline in Europe.
Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. In early 2026, Waters merged with BD's life science and diagnostics business, which increased its concentration in diagnostics (versus none now) and discovery-related life science tools.